论文部分内容阅读
目的 探讨粪便钙卫蛋白(calprotectin)对炎症性肠病(inflammatory bowel disease,IBD)的临床应用价值.方法 收集结肠镜取病理标本确诊IBD的患者79例,其中溃疡性结肠炎(ulcerative colitis,UC)患者47例、克罗恩病(Crohn’s disease,CD)患者32例；腹痛、腹泻等肠道炎症除外IBD患者42例作为疾病对照组；健康体检者34例作为健康对照组,采用ELISA方法检测各组粪便中钙卫蛋白水平.结果 钙卫蛋白在IBD组、疾病对照组和健康对照组中的阳性率分别为57.0％；19.0％；0,IBD组阳性率显著高于其它两组(P＜0.05)；79例IBD患者粪便钙卫蛋白浓度[(493.86±204.18) μg/g]高于疾病对照组[(71.46 ±60.51) μg/g]和健康对照组[(36.19±13.46) μg/g](P＜0.05)；IBD活动期钙卫蛋白浓度[(1015.23±324.96)μg/g]显著高于静止期[(52.69±34.71) μg/g](P＜0.01).结论 粪便钙卫蛋白检测有助于IBD的早期诊断,并可作为IBD活动性的判断指标,具有临床推广价值.,Objective To investigate the clinical application of fecal calprotectin in inflammatory bowel disease (IBD).Methods Colonoscopy took 79 patients with IBD that were diagnosed with pathology,including 47 cases of ulcerative colitis (UC) patients,32 cases of Crohn’s disease (CD).Moreover,42 cases of IBD patients without abdominal pain,diarrhea and other intestinal inflammation were used as disease control group,and 34 cases of healthy people were used as healthy control group.The level of fecal calprotectin in each group was detected by enzyme-linked immunosorbent assay (ELISA).Results The positive rate of fecal Calprotectin in IBD group,disease control group and the healthy control group was 57.0％,19.0％,and 0,respectively; each positive rate in IBD group was significantly higher than the other two groups (P ＜ 0.05).The serum concentration of fecal calprotectin in IBD group [(493.86 ±204.18) μg/g] was significantly higher than the disease control group [(71.46 ± 60.51) μg/g] and the healthy control group [(36.19 ± 13.46) μg/g] (P ＜ 0.05) ; IBD active calprotection [(1015.23 ± 324.96) μg/g] was significantly higher than resting [(52.69 ±34.71) μg/g] (P ＜0.01).Conclusions Fecal calprotectin test benefits early diagnosis of IBD,and may be taken as the diagnostic index of IBD activity.It has extensively clinical value.